Pre-clinical companies

Syncona’s pre-clinical portfolio companies are developing their pipelines, proprietary platforms and progressing towards entering clinical trials.

Syncona’s pre-clinical portfolio comprises companies with a broad range of focuses including: repairing inflammatory organ damage, chronic renal diseases, induced pluripotent stem cell (iPSC)-derived medicines, oncology and protein homeostasis using a variety of modalities, including cell therapy, gene therapy and small molecules.

Key facts

Unless stated all financials at 30 June 2023


Value of pre-clinical portfolio




Portfolio company Board seats

Our pre-clinical portfolio companies